Henagliflozin for liver fat in diabetes and fatty liver
Part of Digestive system, Hormones & metabolism clinical trials.
This study tests whether a medicine called henagliflozin can help reduce fat in the liver for people with type 2 diabetes and non-alcoholic fatty liver disease. It may help improve liver health and blood sugar control at the same time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with type 2 diabetes within the last 5 years.
- You also have non-alcoholic fatty liver disease (NAFLD).
- Your blood sugar is fairly well-controlled with diet and exercise, or you take 1 or 2 diabetes pills (like metformin or sulfonylurea) for at least 8 weeks.
- Your most recent HbA1c (average blood sugar test) is between 7.0% and 8.5%.
- You do not have serious heart, liver, kidney, or other major health problems that could interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if adding a diabetes medicine called an SGLT2 inhibitor to your current treatment can help prevent liver complications in people with chronic hepatitis B and type 2 diabetes or prediabetes. If you have early liver scarring and stable diabetes treatment, this could offer extra protection for your liver.
This study tests whether a diabetes medicine called henagliflozin can reduce liver scarring in people who have both fatty liver disease (MASLD) and type 2 diabetes. If you qualify, you may receive the study drug and help researchers learn if it can improve liver health.
This study tests whether a class of diabetes drugs called SGLT2 inhibitors can help reduce fat in the liver for people with type 2 diabetes and chronic kidney disease. If you have both conditions, this treatment might improve your liver health.
This trial studies whether erugliflozin can reduce liver fat and liver scarring (fibrosis) while also improving blood sugar in people with type 2 diabetes and fatty liver disease (NASH/NAFLD). It’s designed for people who haven’t used certain diabetes medicines like SGLT2 inhibitors or insulin before.
This trial tests a diabetes drug called empagliflozin to see if it can reduce fat and inflammation in the liver in people with a specific type of fatty liver disease called NASH. It may help if you have NASH and either have type 2 diabetes or don't have it.
This study tests a medicine called henagliflozin to see if it helps people with obesity (but not diabetes) lose weight. It is a pill taken by mouth, and the study will compare its effects on weight over time.
Hear when a new Type2 Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.